Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-2136b in Advanced Solid Tumors
NCT05769075Phase 1Recruiting
- Sponsor
- TYK Medicines
- Start
- Apr 2023
- Primary completion
- Jan 2025
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of ty-2136b in solid tumor (2 arms), sponsored by TYK Medicines. Primary endpoints: Dose Limiting Toxicities at 28 days, Recommended Phase 2 Dose and 2 more. Started Apr 2023; status: recruiting.
02
Drugs
ty-2136b
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05769075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05769075.